Myopia And Presbyopia Treatment MarketSize, Share & Industry Analysis, 2026-2034By TypeBy IndicationBy End UserBy Age GroupBy Payer Type

Myopia and presbyopia treatment products correct or manage the two most common refractive vision disorders: nearsightedness that typically develops in childhood and the age-related loss of near focus that affects nearly every adult past midlife. The category spans everyday corrective eyewear and contact lenses through implantable and surgical options used during cataract and refractive procedures, along with emerging pharmacological and orthokeratology approaches aimed at slowing myopia progression in children. Buyers range from individual patients purchasing through optical retailers and online channels to hospitals and ophthalmic surgery centers procuring implantable lenses and diagnostic equipment.

The global myopia and presbyopia treatment market stood at USD 22.5 billion in 2025. A forecast-period rate of 8.38% takes it to USD 46.35 billion by 2034, and the study reports every year in between, passing USD 14.8 billion in 2020, USD 20.85 billion in 2024, USD 24.35 billion in 2026 and USD 33.65 billion in 2030.

34% of 2025 revenue sits in Eyeglasses, worth USD 7.65 billion and rising to USD 12.98 billion at 28% by 2034, the largest type line in both years. Growth is fastest in Other at 10.72% and slowest in Eyeglasses at 6.04%. Intra Ocular Lenses and Other take share over the period; Eyeglasses and Contact Lenses give it up while still growing in absolute terms.

The indication split puts Myopia first, at USD 10.35 billion and 46% of revenue in 2025, rising to USD 20.39 billion and 43.99% in 2034. Combined (Dual Condition) grows faster at 9.21% against 7.82%, moving from 14% of revenue to 15.02% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

Asia Pacific is the largest region at 36% of 2025 revenue, worth USD 8.1 billion and reaching USD 18.54 billion by 2034. North America follows at 28%, moving from USD 6.3 billion to USD 11.59 billion, and Middle East and Africa is the smallest at 6%. Because Asia Pacific and Latin America take share, the revenue added by 2034 concentrates rather than spreading across all five regions.

Coverage extends to five regions, four type lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies rather than a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• A forecast-period rate of 8.38% takes the market from USD 22.5 billion in 2025 to USD 46.35 billion in 2034, against 8.74% recorded over the 2020-2025 historical period.
• The largest line by type is Eyeglasses, worth USD 7.65 billion and 34% of revenue in 2025, rising to USD 12.98 billion and 28% by 2034.
• At 10.72%, Other grows faster than any other type line, moving from USD 3.15 billion and 14% of revenue in 2025 to USD 7.88 billion and 17% in 2034.
• Against a base case of USD 46.35 billion in 2034, the study also reports a bear case at USD 42.5 billion and a bull case at USD 50.2 billion, with the assumptions behind each set out separately.
• Asia Pacific holds 36% of global revenue in 2025 at USD 8.1 billion, the largest of the five regions tracked, and reaches USD 18.54 billion by 2034.
• China accounts for 40% of Asia Pacific in the base year, worth USD 3.24 billion in 2025 and reaching USD 7.42 billion by 2034, the worked country example carried through that region's chapters.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.

Three movements define the forecast period in the global myopia and presbyopia treatment market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Other grows faster than Eyeglasses. 10.72% against 6.04%: that gap, between Other and Eyeglasses, is the largest on the type axis. Shares follow: 14% to 17% for Other, 34% to 28% for Eyeglasses. The revenue figures behind that are USD 3.15 billion to USD 7.88 billion and USD 7.65 billion to USD 12.98 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Regional weight shifts toward Asia Pacific and Latin America. Asia Pacific moves from 36% of revenue in 2025 to 40% in 2034, worth USD 8.1 billion rising to USD 18.54 billion; Latin America moves from 8% of revenue in 2025 to 9% in 2034, worth USD 1.8 billion rising to USD 4.17 billion. Share moves off the others in turn: North America at 28% moving to 25%, Europe at 22% moving to 20%, Middle East and Africa at 6% moving to 6%, each still growing in revenue terms. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

The series never breaks trajectory. The market moves through USD 14.8 billion in 2020, USD 20.85 billion in 2024, USD 22.5 billion in 2025, USD 24.35 billion in 2026, USD 33.65 billion in 2030 and USD 46.35 billion in 2034. No year breaks the trajectory, and the 8.38% forecast rate compares with 8.74% recorded over 2020-2025, a continuation rather than an inflection. For a participant that makes planning a question of capturing a share of steady expansion rather than timing a discontinuity, and it is why the type and regional mixes matter more to a forecast than the headline rate does.

Other carries the market's growth rate

Three sources account for the growth to 2034: 8.38% compounding across the base, share moving toward the faster type lines, and above-market expansion in the leading regions.

What holds the forecast back

What the bull case turns on

Revenue is concentrated in Eyeglasses

In North America, 28% of global revenue puts 2025 at USD 6.3 billion rising to USD 11.59 billion in 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

Share settles at 25% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

Within the region the type split tracks the global one; 34% of 2025 revenue in Eyeglasses, fastest growth of 10.72% in Other. Per-axis and per-country detail for North America sits in the full report.

The largest single market in North America is the United States, at USD 5.36 billion in 2025 and USD 9.74 billion in 2034. At 85.08% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 6.3 billion to USD 11.59 billion over the same period, and this is the market carrying the country-level detail in the full report.

The type pattern in the United States is the global one: 34% of 2025 revenue in Eyeglasses, 28% by 2034, against 10.72% growth in Other taking it from 14% to 17%. Its 85.08% weight in North America means those movements carry straight into the regional totals. Per-type revenue for the United States appears on its own in the full report.

In the United States, products used to treat myopia and presbyopia fall under the Food and Drug Administration's oversight, split between its device and drug centers depending on the product type. Spectacle and contact lenses, orthokeratology lenses, implantable lenses, and laser refractive systems are regulated as medical devices, requiring either premarket notification or premarket approval depending on risk classification, along with adherence to quality system regulations covering manufacturing and labelling. Pharmacological treatments, such as eye drops aimed at slowing myopia progression or improving near vision, are regulated as drugs, requiring a new drug application supported by clinical evidence before marketing. Prescription-dispensing requirements and truthful labelling obligations apply across both categories, and post-market adverse event reporting is mandatory for manufacturers.

In the United States the field is Topcon Corporation, Carl Zeiss AG, Bausch + Lomb Corporation, Nidek Co., Ltd, Novartis AG, Johnson & Johnson Vision, Alcon Inc., EssilorLuxottica, The Cooper Companies (CooperVision), HOYA Corporation, STAAR Surgical Company and Menicon Co., Ltd. Volume sits in Eyeglasses at 34% of 2025 revenue; movement sits in Other at 10.72% growth. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 0.76 billion in 2025, rising to USD 1.45 billion by 2034; 3.38% of global revenue and 12.06% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 22% of global revenue puts 2025 at USD 4.95 billion rising to USD 9.27 billion in 2034. Among the five regions it ranks third by revenue in both years.

20% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Eyeglasses leads here as it does globally, at 34% of 2025 revenue, and Other again grows fastest at 10.72%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

30.1% of Europe's base-year revenue comes from Germany; USD 1.49 billion, rising to USD 2.78 billion by 2034. At 30.1% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Against regional totals of USD 4.95 billion in 2025 and USD 9.27 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in Germany is the global one: 34% of 2025 revenue in Eyeglasses, 28% by 2034, against 10.72% growth in Other taking it from 14% to 17%. With 30.1% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Germany by type separately.

Germany applies the European Union's Medical Device Regulation to lenses, orthokeratology products, implantable lenses, and laser-based correction systems, requiring conformity assessment by a Notified Body and CE marking before a product can be placed on the market. The Federal Institute for Drugs and Medical Devices oversees vigilance and market surveillance domestically, working alongside the broader EU framework. Where treatment involves a pharmaceutical, such as drops intended to manage presbyopia or myopia progression, marketing authorisation follows the EU or national pharmaceutical approval route, with labelling, patient information, and manufacturing standards aligned to European pharmacopoeial requirements. Suppliers must maintain technical documentation, risk classification records, and post-market surveillance systems to remain compliant with ongoing regulatory obligations.

The suppliers tracked in this study (Topcon Corporation, Carl Zeiss AG, Bausch + Lomb Corporation, Nidek Co., Ltd, Novartis AG, Johnson & Johnson Vision, Alcon Inc., EssilorLuxottica, The Cooper Companies (CooperVision), HOYA Corporation, STAAR Surgical Company and Menicon Co., Ltd) compete in Germany across the type lines above. Two different problems sit on the same axis: holding Eyeglasses at 34% of 2025 revenue, and taking Other while it grows at 10.72%.

The United Kingdom is sized at USD 1.09 billion in 2025, rising to USD 2.04 billion by 2034; 4.84% of global revenue and 22.02% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Within Europe, France accounts for 17.98% of regional revenue and 3.96% of the global total, worth USD 0.89 billion in 2025 and USD 1.67 billion by 2034.

USD 8.1 billion of 2025 revenue is generated in Asia Pacific, 36% of the global myopia and presbyopia treatment market with USD 18.54 billion projected for 2034. Among the five regions it ranks first by revenue in both years.

Share climbs to 40% by 2034, on growth above the market's own 8.38%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the type split tracks the global one; 34% of 2025 revenue in Eyeglasses, fastest growth of 10.72% in Other. Asia Pacific is reported axis by axis and country by country in the full study.

China is the largest market within Asia Pacific, generating USD 3.24 billion in 2025 and projected to reach USD 7.42 billion by 2034. At 40% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 8.1 billion in 2025 and USD 18.54 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The type pattern in China is the global one: 34% of 2025 revenue in Eyeglasses, 28% by 2034, against 10.72% growth in Other taking it from 14% to 17%. Since 40% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Revenue by type for China is reported separately in the full report.

In China, the National Medical Products Administration governs both device-based and pharmaceutical approaches to treating myopia and presbyopia. Contact lenses, orthokeratology lenses, implantable lenses, and refractive surgical equipment are classified by risk tier, with higher-risk categories requiring clinical evaluation and a registration certificate before sale, alongside compliance with national medical device standards covering safety and manufacturing quality. Pharmaceutical products intended for myopia control or presbyopia relief must undergo the agency's drug registration pathway, including efficacy and safety review specific to the domestic market. Imported products generally require a local agent and adherence to Chinese labelling and packaging conventions. Ongoing post-market surveillance and adverse event reporting obligations apply to both device and drug categories under this framework.

Topcon Corporation, Carl Zeiss AG, Bausch + Lomb Corporation, Nidek Co., Ltd, Novartis AG, Johnson & Johnson Vision, Alcon Inc., EssilorLuxottica, The Cooper Companies (CooperVision), HOYA Corporation, STAAR Surgical Company and Menicon Co., Ltd are the suppliers covered in China. Two different problems sit on the same axis: holding Eyeglasses at 34% of 2025 revenue, and taking Other while it grows at 10.72%.

7.91% of global revenue is generated in Japan; USD 1.78 billion in 2025, reaching USD 3.89 billion in 2034, and 21.98% of Asia Pacific.

Within Asia Pacific, South Korea accounts for 11.98% of regional revenue and 4.31% of the global total, worth USD 0.97 billion in 2025 and USD 2.22 billion by 2034.

In Latin America, 8% of global revenue puts 2025 at USD 1.8 billion rising to USD 4.17 billion in 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

Share climbs to 9% by 2034, because it outgrows the market's 8.38%; the revenue added here is disproportionate to where the region started.

The type mix reported at global level applies here, with Eyeglasses the largest line at 34% of 2025 revenue and Other the fastest-growing at 10.72%. The full report breaks Latin America out along every axis and by country.

The largest single market in Latin America is Brazil, at USD 0.81 billion in 2025 and USD 1.88 billion in 2034. Its 45% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Set against USD 1.8 billion and USD 4.17 billion for the region, it is why this market rather than a smaller one is the one reported in full.

The type pattern in Brazil is the global one: 34% of 2025 revenue in Eyeglasses, 28% by 2034, against 10.72% growth in Other taking it from 14% to 17%. With 45% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Brazil carries its own type breakdown in the full report.

Brazil's National Health Surveillance Agency, ANVISA, regulates both the medical devices and pharmaceutical products used in treating myopia and presbyopia. Lenses, orthokeratology products, implantable correction devices, and laser refractive equipment must be registered according to their assigned risk classification, with higher-risk categories subject to more extensive technical and clinical documentation before authorisation is granted. Manufacturers must also demonstrate compliance with Good Manufacturing Practice requirements, which the agency verifies through inspection. Pharmaceutical treatments follow a separate but parallel registration route requiring evidence of safety and efficacy suited to local review. Labelling must appear in Portuguese and meet the agency's packaging and information disclosure standards, and importers are required to maintain a local regulatory representative.

Competition in Brazil runs between the suppliers this study tracks: Topcon Corporation, Carl Zeiss AG, Bausch + Lomb Corporation, Nidek Co., Ltd, Novartis AG, Johnson & Johnson Vision, Alcon Inc., EssilorLuxottica, The Cooper Companies (CooperVision), HOYA Corporation, STAAR Surgical Company and Menicon Co., Ltd. Eyeglasses, at 34% of 2025 revenue, is where the volume sits, and Other, growing at 10.72%, is where position changes hands over the forecast period.

Within Latin America, Mexico accounts for 25% of regional revenue and 2% of the global total, worth USD 0.45 billion in 2025 and USD 1.04 billion by 2034.

USD 1.35 billion of 2025 revenue is generated in Middle East and Africa, 6% of the global myopia and presbyopia treatment market with USD 2.78 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

6% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Eyeglasses leads here as it does globally, at 34% of 2025 revenue, and Other again grows fastest at 10.72%. The full report breaks Middle East and Africa out along every axis and by country.

USD 0.41 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.83 billion by 2034. It accounts for 30.37% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 1.35 billion in 2025 and USD 2.78 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Eyeglasses at 34% of 2025 revenue, easing to 28% by 2034, and the fastest is Other at 10.72%, from 14% to 17%. With 30.37% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for Saudi Arabia is reported separately in the full report.

In Saudi Arabia, the Saudi Food and Drug Authority regulates both device and pharmaceutical treatments for myopia and presbyopia. Lenses, orthokeratology products, implantable lenses, and laser-based correction systems must be listed on the national medical device registry, with classification and conformity assessment expectations broadly aligned to international frameworks, and manufacturers or their authorised local representatives responsible for registration and labelling in Arabic alongside technical documentation. Pharmaceutical treatments require marketing authorisation through the authority's drug registration process, supported by safety and efficacy evidence. The authority also participates in harmonisation efforts across the Gulf Cooperation Council, so conformity with shared regional standards can support recognition across neighbouring markets. Post-market vigilance and reporting obligations apply once a product is authorised for sale.

In Saudi Arabia the field is Topcon Corporation, Carl Zeiss AG, Bausch + Lomb Corporation, Nidek Co., Ltd, Novartis AG, Johnson & Johnson Vision, Alcon Inc., EssilorLuxottica, The Cooper Companies (CooperVision), HOYA Corporation, STAAR Surgical Company and Menicon Co., Ltd. The commercially relevant division is 34% of 2025 revenue in Eyeglasses, where the volume is, against 10.72% growth in Other, where share moves.

1.33% of global revenue is generated in the United Arab Emirates; USD 0.3 billion in 2025, reaching USD 0.61 billion in 2034, and 22.22% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Indication, End User, Age Group, Payer Type, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.